Loading…
Develops in-vivo CRISPR gene-editing therapies designed to permanently edit genes inside the body for genetic diseases.
Develops in-vivo CRISPR gene-editing therapies designed to permanently edit genes inside the body for genetic diseases.
No medicine is on the market, so cash comes from selling shares and from Regeneron, which shares development costs and, if approved, profit on NTLA-2001, a one-time infusion meant to switch off a disease-causing gene. NTLA-2002 is wholly owned, so Intellia would keep its profit.
Moat: narrow (IP / patents, process know-how). Among the first to demonstrate in-vivo CRISPR editing in humans, with foundational patents and a Regeneron partnership.
Headquarters: Cambridge, Massachusetts, US · Founded: 2014 · Employees: 377
Size Intellia Therapeutics (NTLA) is a United States Health Care company (Biotechnology) with a market value of $1.59B, the 1949th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.35 on 6 Nov 2026.
Performance Over six months the shares fell 19.4%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 12.6% over the last twelve months (peer median +27.5%); the operating margin is -711.7% (peer median -25.7%).
Valuation It trades at 20.6× enterprise value to sales against a peer median of 14.8× (8th most expensive of 18).
Capital Return on invested capital runs 105.7 points below its cost of capital (13.7% WACC).
Short interest Short interest is 31.7% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $59.5M | $67.7M | $57.9M | $36.3M | $52.1M |
| Revenue growth | — | +17% | +60% | -30% | — |
| Gross profit | $44.3M | $51.7M | $47.6M | $27.3M | $44.5M |
| EBITDA | -$408M | -$425M | -$524M | -$506M | -$451M |
| Net income | -$400M | -$413M | -$519M | -$481M | -$474M |
| Free cash flow | -$349M | -$396M | -$355M | -$408M | -$347M |
| Capital expenditure | $2.04M | $1.13M | $5.78M | $14.0M | $13.6M |
| Total debt | $73.4M | $93.3M | $210M | $115M | $131M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Intellia Therapeutics NTLA | $1.59B | -19% | +13% | -712% | 20.6× | n/a |
| CRISPR Therapeutics CRSP | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a |
| Beam Therapeutics BEAM | $2.73B | -18% | +163% | -268% | 13.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NTLA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.9% | -7.7% | 10th lowest of 21 |
| 6-month return | -19.4% | -10.9% | 7th lowest of 19 |
| Distance from 52-week high | -38.6% | -43.3% | 9th highest of 21 |
| Revenue growth (TTM) | +12.6% | +27.5% | 4th lowest of 19 |
| Operating margin | -711.7% | -25.7% | 6th lowest of 19 |
| EV / Sales | 20.6× | 14.8× | 8th most expensive of 18 |
| ROIC minus cost of capital | -105.7 pp | -11.2 pp | 2nd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |